

07/02/2020

Dear User

RE: Change in the Myositis Immunoblot repertoire offered at Oxford Immunology

From the 10th February, Oxford will be offering an extended myositis immunoblot repertoire instead of the current assay. The new assay contains all of the antigens present on the existing immunoblot but also contains 5 new antigens. The details of this can be seen below:

Existing Myositis immunoblot antigens

Antigen	Indication
Ku	Anti-synthetase syndrome
Jo-1	Anti-synthetase syndrome
PL-7	Anti-synthetase syndrome
PL-12	Anti-synthetase syndrome
EJ	Anti-synthetase syndrome
OJ	Anti-synthetase syndrome
SRP	Necrotising myositis
PMscl-100	Polymyositis/scleroderma overlap
PMscl-75	Polymyositis/scleroderma overlap
Mi-2	Dermatomyositis

Additional antigens included in new myositis immunoblot

Antigen	Indication
TIF-1gamma	Dermatomyositis – associated with malignancy
MDA-5	Dermatomyositis – associated with malignancy
NXP	Dermatomyositis
SAE1	Dermatomyositis
C5N-1A	Inclusion body myositis

Please note on the new immunoblot, Mi-2 antibodies will be split into 2 separate results, Mi-2alpha and Mi-2beta, their clinical indication remains the same. C5N-1A will not be available initially, we will be aiming to have this available for testing in the next few months

The cut-off for equivocal and positive results will remain the same as the existing assay and our advice surrounding equivocal results will not be changing. The price of the assay will not be changing at this time.

Please contact us if you have any further questions

Kind regards

Dr Ross Sadler
Clinical Lead for Laboratory Immunology